<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>N-(2S, 3R)-3-amino-2-hydroxy-4-phenylbutyryl-<z:chebi fb="0" ids="15603,30006">L-leucine</z:chebi> (ubenimex) was administered orally, to patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> derived from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, in a multi-institute study </plain></SENT>
<SENT sid="1" pm="."><plain>Out of 77 patients evaluated, one achieved a complete remission, three a good response and two a partial response while 71 failed to respond to a daily oral administration of 30 mg ubenimex </plain></SENT>
<SENT sid="2" pm="."><plain>The overall response rate was 7.8% (95% confidence limits; 3.6-16.0%); 7.0% (3.0-15.4%) in 71 MDS and 16.6% (3.0-56.3%) in <z:hpo ids='HP_0011009'>acute</z:hpo> six <z:hpo ids='HP_0001909'>leukemias</z:hpo> derived from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Responses continued for six to 24 (median 10.5) weeks </plain></SENT>
<SENT sid="4" pm="."><plain>No serious hematologic, biochemical or clinical toxicity was encountered, except for gastro-intestinal (GI) toxicity in one patient </plain></SENT>
<SENT sid="5" pm="."><plain>The present study demonstrated ubenimex not to be generally beneficial for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, and not to be recommended as a standard treatment for the disease </plain></SENT>
</text></document>